强化胰岛素治疗对重型颅脑创伤应激性高血糖患者HMGB1/NF-κB通路的影响
该研究纳入61例GCS≤8、随机血糖三次>11.1 mmol/L且HbA1c<0.065的重型颅脑创伤应激性高血糖患者,随机分为强化胰岛素治疗组(目标血糖4.4-7.8 mmol/L)和常规血糖治疗组(目标血糖7.8-12.2 mmol/L)。最终52例纳入分析(常规组28例,强化组24例)。两组炎症指标在治疗后1天达峰后逐渐下降;强化组治疗后7天CRP和TNF-α显著低于常规组,治疗后14天HMGB1和NF-κB p65表达显著低于常规组。作者结论认为强化胰岛素治疗通过HMGB1/NF-κB通路抑制sTBI应激性高血糖患者的炎症反应。
要点
- 强化胰岛素治疗组目标血糖4.4-7.8 mmol/L,常规血糖治疗组目标血糖7.8-12.2 mmol/L,用于GCS≤8且随机血糖三次>11.1 mmol/L、HbA1c<0.065的sTBI患者。
- 治疗7天时强化组CRP 36.7±4.4 mg/L vs 常规组45.1±6.1 mg/L,TNF-α 42.4±9.7 ng/L vs 53.2±9.1 ng/L,均P<0.05。
- 治疗14天时强化组HMGB1 60.1±8.7 μg/L vs 常规组80.5±9.1 μg/L,NF-κB p65(ΔCt)35.8±8.5 vs 53.5±7.3,均P<0.05。
- 两组HMGB1、TNF-α、CRP及NF-κB基因表达在治疗后1天均较治疗前显著升高并达峰值,治疗7天时显著低于1天。
- 61例中9例因连续4次血糖监测未达目标值、合并严重感染或放弃治疗而退出观察,最终52例纳入分析。
适用人群与场景
- 纳入2015年7月至2017年10月南京医科大学附属淮安第一医院收治的重型颅脑创伤患者,GCS≤8,三次随机血糖>11.1 mmol/L,HbA1c<0.065。
- 最终分析52例:常规血糖治疗组28例,强化胰岛素治疗组24例。
诊断标准与关键阈值
- 应激性高血糖诊断条件:GCS≤8,三次随机血糖水平>11.1 mmol/L,HbA1c<0.065。
- 强化胰岛素治疗组血糖目标值4.4-7.8 mmol/L;常规血糖治疗组血糖目标值7.8-12.2 mmol/L。
处置流程与药物剂量
- 强化胰岛素治疗组:维持血糖在4.4-7.8 mmol/L。
- 常规血糖治疗组:维持血糖在7.8-12.2 mmol/L。
- 因连续4次血糖监测未达到目标值、合并严重感染或放弃治疗而退出观察。
研究设计与关键结果
- 研究类型为随机对照研究,纳入61例sTBI伴应激性高血糖患者,随机分为强化胰岛素治疗组(29例)和常规血糖治疗组(32例),最终52例纳入分析(常规组28例,强化组24例)。
- 治疗后1天两组血浆HMGB1、TNF-α、CRP及单核细胞NF-κB基因表达均较治疗前显著升高并达峰值,此后逐渐下降,治疗7天时显著低于1天。
- 治疗7天时强化组CRP显著低于常规组(36.7±4.4 mg/L vs 45.1±6.1 mg/L,P<0.05),TNF-α显著低于常规组(42.4±9.7 ng/L vs 53.2±9.1 ng/L,P<0.05)。
- 治疗14天时强化组HMGB1显著低于常规组(60.1±8.7 μg/L vs 80.5±9.1 μg/L,P<0.05),单核细胞NF-κB p65表达显著低于常规组(ΔCt:35.8±8.5 vs 53.5±7.3,P<0.05)。
证据类型、等级与局限
- 证据类型:随机对照研究(随机数字表法分组)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,强化胰岛素治疗通过HMGB1/NF-κB通路抑制sTBI伴应激性高血糖患者的炎症反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effect of intensive insulin therapy (IIT) on high mobility group box-1/nuclear factor-ΚB (HMGB1/NF-ΚB) signaling pathway in severe traumatic brain injury (sTBI) patient with stress hyperglycemia.
METHODS: Sixty-one sTBI patients with stress hyperglycemia [Glasgow coma scale (GCS) ≤ 8, three times of random blood glucose levels > 11.1 mmoL/L, glycosylated hemoglobin (HbA1c) < 0.065] admitted to the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University from July 2015 to October 2017 were enrolled. Patients were divided into IIT group (29 cases, keeping blood glucose at 4.4-7.8 mmol/L) and conventional glycemic therapy (CGT) group (32 cases, keeping blood glucose at 7.8-12.2 mmo/L) according to the random number table method. Before treatment and 1, 7 and 14 days after treatment, the levels of plasma HMGB1 and tumor necrosis factor-α (TNF-α) were measured by enzyme linked immunosorbent assay (ELISA); C-reactive protein (CRP) was determined by automatic biochemical analyzer, and NF-ΚB p65 gene expression in peripheral blood mononuclear cells was detected by real-time quantitative polymerase chain reaction (PCR).
RESULTS: Nine patients were withdrawn from the observation because the 4 consecutive blood glucose monitoring did not reach the target value, combined with severe infection, or abandoned the treatment with serious brain damage. Finally, 52 patients were enrolled in the analysis, including 28 in CGT group and 24 in IIT group. The levels of plasma HMGB1, TNF-α, CRP and the expression of NF-ΚB gene in monocytes of the two groups at 1 day after treatment were significantly higher than those before treatment, and reached the peak value, then gradually decreased. After 7 days of treatment, they were significantly lower than 1 day. The levels of plasma CRP and TNF-α in the IIT group were significantly lower than those in the CGT group [CRP (mg/L): 36.7±4.4 vs. 45.1±6.1, TNF-α (ng/L): 42.4±9.7 vs. 53.2±9.1, both P < 0.05], the level of HMGB1 in plasma and the expression of NF-ΚB p65 in monocytes were significantly lower than those in the CGT group after 14 days of treatment [HMGB1 (μg/L): 60.1±8.7 vs. 80.5±9.1, NF-ΚB p65 (ΔCt): 35.8±8.5 vs. 53.5±7.3, both P < 0.05].
CONCLUSIONS: IIT inhibits the inflammatory response in sTBI patients with stress hyperglycemia through HMGB1/NF-ΚB pathway.
参考来源
- Zhu X, Zhang H, Shang F, et al. [Effect of intensive insulin therapy on high mobility group box-1/nuclear factor-ΚB pathway in severe traumatic brain injury patient with stress hyperglycemia]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31537217. doi:10.3760/cma.j.issn.2095-4352.2019.08.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。